Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome

Published:2019-03-01 Issue:5 Volume:8 Page:e1581530
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Liu Jing¹,O’Donnell Jake S.¹²³,Yan Juming¹³,Madore Jason²,Allen Stacey¹,Smyth Mark J.²³,Teng Michele W. L.¹³

Affiliation:

1. Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia

2. Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia

3. School of Medicine, University of Queensland, Herston, Australia

Funder

National Health and Medical Research Council of Australia (NH&MRC) Career Development Fellowship

Project Grant

Senior Principal Research Fellowship

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2019.1581530

Reference19 articles.

1. The future of immune checkpoint therapy

2. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

3. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

4. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

5. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study;Cancer Immunology, Immunotherapy;2024-08-06

2. Immunotherapy for head and neck cancer: Fundamentals and therapeutic development;Auris Nasus Larynx;2024-08

3. Impact of treatment interval between neoadjuvant immunochemotherapy and surgery in lung squamous cell carcinoma;BMC Cancer;2024-05-13

4. Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study;American Journal of Transplantation;2024-04

5. Circulating tumor-associated antigen-specific IFNγ+4-1BB+ CD8+ T cells as peripheral biomarkers of treatment outcomes in patients with pancreatic cancer;Frontiers in Immunology;2024-03-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3